While these results, combined with omalizumab’s possible efficacy in COVID-19 may suggest a specific role for IgE or type II immunity in the pathogenesis of COVID-19, they may also merely be indicative of global immune dysregulation (7). This evidence concerns the gene IGHE and COVID-19.